Rize Oncology Inc.
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.47% | 20.06% | 8.63% | 34.46% | 16.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.98% | 113.17% | 62.13% | 49.46% | 0.35% |
| Operating Income | -74.98% | -113.17% | -62.13% | -49.46% | -0.35% |
| Income Before Tax | -81.23% | -127.17% | -73.15% | -62.03% | -7.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -81.23% | -127.17% | -73.15% | -62.03% | -7.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.23% | -127.17% | -73.15% | -62.03% | -7.02% |
| EBIT | -74.98% | -113.17% | -62.13% | -49.46% | -0.35% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -12.06% | -16.20% | -1.68% | -9.21% | 7.84% |
| Normalized Basic EPS | -12.50% | -18.18% | -2.70% | -10.64% | 7.37% |
| EPS Diluted | -12.06% | -16.20% | -1.68% | -9.21% | 7.84% |
| Normalized Diluted EPS | -12.50% | -18.18% | -2.70% | -10.64% | 7.37% |
| Average Basic Shares Outstanding | 65.27% | 96.68% | 69.27% | 36.57% | 7.87% |
| Average Diluted Shares Outstanding | 65.27% | 96.68% | 69.27% | 36.57% | 7.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |